ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2782

Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial

Eli Miloslavsky1, Ulrich Specks2, Peter A Merkel3, Philip Seo4, Robert F. Spiera5, Carol A. Langford6, Gary S. Hoffman7, Cees G.M. Kallenberg8, E. William St Clair9, Nadia Tchao10, Linna Ding11, David Ikle12, Brett Jepson12, Paul Brunetta13 and John H. Stone14, 1Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 9Medicine, Duke Unversity Medical Center, Durham, NC, 10Immune Tolerance Network, Bethesda, MD, 11NIAID, Bethesda, MD, 12Rho, Chapel Hill, NC, 13Biotherapeutics, Genentech, So San Francisco, CA, 14Rheumatology, Massachusetts General Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ANCA, Rituximab, treatment and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab in ANCA-associated vasculitis (RAVE) trial in order to determine the safety and efficacy of a second course of rituximab for relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

Methods:

Randomized controlled trial comparing rituximab (RTX, n=99) to cyclophosphamide (CYC) followed by azathioprine (AZA, n=98) for remission induction. Patients who suffered a severe disease flare (BVAS/WG > 3 or one major BVAS/WG item) between 6 and 18 months were eligible for open label RTX (OLR) (375mg/m2 once weekly times four).

Results:

17 patients received two courses of RTX.  Baseline characteristics are presented in the table. 

Serial RTX.jpg

After retreatment, patients were followed for an average of 301 days (range 35-427). Treatment with OLR led to remission (BVAS/WG=0) in 15 of 17 patients (88%) by an average of 55 days (range 1-181). One patient with diffuse alveolar hemorrhage did not improve and died 7 weeks after the initial flare.  Another patient reached a BVAS/WG of 1 before suffering a limited flare at 12 months after OLR. 

Six months after OLR, 15 patients (88%) were in remission (BVAS/WG = 0), 8 (47%) had achieved complete response (BVAS/WG = 0 and prednisone ≤ 10mg/day) and 6 patients (35%) were in complete remission (BVAS/WG = 0 and prednisone = 0).  After 12 months, 13 patients (76%) had achieved complete responses and 8 (47%) had reached complete remission.  There were 4 limited and no severe flares among the 17 patients (BVAS/WG 2.5) over one year of follow up after OLR. 

There were a total of 3 severe (grade ≥ 3) adverse events after OLR, including one death (described above), metastatic colon cancer, and severe sinusitis.

Conclusion:

This prospective study indicates that retreatment of GPA or MPA flares with rituximab is effective in re-inducing remission.

           


Disclosure:

E. Miloslavsky,

Genentech Inc,

9;

U. Specks,
None;

P. A. Merkel,
None;

P. Seo,
None;

R. F. Spiera,

Roche Pharmaceuticals, g,

2;

C. A. Langford,

Bristol-Myers Squibb,

9,

Genentech and Biogen IDEC Inc.,

9;

G. S. Hoffman,
None;

C. G. M. Kallenberg,

Roche,

8;

E. W. St Clair,
None;

N. Tchao,
None;

L. Ding,
None;

D. Ikle,

Rho,

3;

B. Jepson,

Rho,

3;

P. Brunetta,

Genentech Inc,

3;

J. H. Stone,

Genentech and Biogen IDEC Inc.,

2,

Genentech and Biogen IDEC Inc.,

5,

Roche Pharmaceuticals,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retreatment-with-rituximab-in-the-rituximab-in-anca-associated-vasculitis-rave-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology